New Findings From Phase 1B Study of OTO-104

Otonomy, Inc., a clinical stage biopharmaceutical company, presented study data demonstrating that both the 3 mg and 12 mg OTO-104 doses were associated with improvement in tinnitus as measured by the Tinnitus Handicap Inventory (THI-25).

THI is a clinically validated patient-reported measure that can be used to quantify the impact of tinnitus on activities of daily living. Both OTO-104 doses resulted in reductions in THI Total Score from baseline as early as one month following treatment. Click to learn more.